• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Supernus Pharmaceuticals Inc.

    6/17/24 5:15:42 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SUPN alert in real time by email
    S-8 1 tm2417018d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on June 17, 2024

     

    Registration No. 333-______     

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

     

    SUPERNUS PHARMACEUTICALS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware 20-2590184
    (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)
       
    9715 Key West Avenue, Rockville, MD 20850
    (Address of principal executive offices) (Zip Code)

     

     

     

    Supernus Pharmaceuticals, Inc. Amended and Restated

    2021 Equity Incentive Plan

    (Full title of the plan)

     

     

     

    Jack A. Khattar

    President and Chief Executive Officer

    Supernus Pharmaceuticals, Inc.

    9715 Key West Avenue

    Rockville, Maryland 20850

    (301) 838-2500

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

     

    Copies of all communications to:

     

    Mark I. Gruhin

    George A. Naya

    Saul Ewing LLP

    1919 Pennsylvania Avenue N.W.

    Suite 550

    Washington, DC 20006-3434

    (202) 333-8800

     

     

     

    See next page for calculation of registration fee.

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer x Accelerated filer ¨
    Non-accelerated filer ¨ Smaller reporting company ¨
        Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement is being filed in order to effect the registration of an additional 4,000,000 shares of Common Stock of Supernus Pharmaceuticals, Inc. (the “Registrant”) under the Registrant’s Amended and Restated 2021 Equity Incentive Plan (the “Equity Plan”). Following the registration of these additional shares, we will have registered an aggregate of 15,012,893 shares of Common Stock to be issued under the Equity Plan. The Company previously filed a Registration Statement on Form S-8 with the Securities and Exchange Commission (the “SEC”) on June 25, 2021 (File No. 333-257392) to register 11,012,893 shares of Common Stock issuable under the Equity Plan. Pursuant to General Instruction E to Form S-8, the contents of the foregoing earlier registration statement on Form S-8 concerning the Equity Plan filed with the SEC is incorporated herein by reference, except to the extent supplemented, amended or superseded by the information set forth herein.

     

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    As permitted by Rule 428 under the Securities Act of 1933, this Registration Statement omits the information specified in Part I of Form S-8. The documents containing the information specified in Part I will be delivered to the participants of the Equity Plan as required by Rule 428(b).

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3.Incorporation of Documents by Reference.

     

    The documents listed in clauses 1 through 5 below are incorporated herein by this reference thereto, and all documents subsequently filed (other than respective filings or portions of filings that are furnished, under applicable SEC rules, rather than filed) by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended, prior to the filing of a post-effective amendment, which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by this reference in this registration statement and to be a part hereof from the date of filing of such documents:

     

    1.The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on February 27, 2024;

     

    2.The Registrant’s Current Reports on Form 8-K, filed with the SEC on February 5, 2024, February 21, 2024, February 28, 2024, April 8, 2024, April 24, 2024 (Date of Report April 22, 2024), May 9, 2024, and June 17, 2024;

     

    3.The Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed with the SEC on May 8, 2024;

     

    4.The Registrant’s Proxy Statement, dated April 29, 2024, for the Registrant’s 2024 annual meeting of stockholders, filed with the SEC on April 29, 2024; and

     

    5.The description of the Registrant’s common stock, $0.001 par value per share, which is contained in the Registrant’s Registration Statement on Form S-3 filed with the SEC on December 3, 2014, including any subsequently filed amendments and reports updating such description.

     

    Item 4.Description of Securities.

     

    Not applicable.

     

    2 

     

     

    Item 5.Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6.Indemnification of Directors and Officers.

     

    The Registrant’s amended and restated certificate of incorporation contains provisions that eliminate, to the maximum extent permitted by the General Corporation Law of the State of Delaware, the personal liability of directors and executive officers for monetary damages for breach of their fiduciary duties as a director or officer. The Registrant’s amended and restated certificate of incorporation and bylaws provides that the Registrant shall indemnify its directors and executive officers and may indemnify its employees and other agents to the fullest extent permitted by the General Corporation Law of the State of Delaware.

     

    Sections 145 and 102(b)(7) of the General Corporation Law of the State of Delaware provide that a corporation may indemnify any person made a party to an action by reason of the fact that he or she was a director, executive officer, employee or agent of the corporation or is or was serving at the request of the corporation against expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him or her in connection with such action if he or she acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of an action by or in right of the corporation, no indemnification may generally be made in respect of any claim as to which such person is adjudged to be liable to the corporation.

     

    The Registrant has entered into indemnification agreements with each of its directors and executive officers, in addition to the indemnification provided for in the Registrant’s amended and restated certificate of incorporation and bylaws, and intends to enter into indemnification agreements with any new directors and executive officers in the future.

     

    The Registrant has purchased and intends to maintain insurance on behalf of any person who is or was a director or officer of the Registrant against any loss arising from any claim asserted against him or her and incurred by him or her in any such capacity, subject to certain exclusions.

     

    Item 7.Exemption from Registration Claimed.

     

    Not applicable.

     

    Item 8.Exhibits.

     

    The following is a list of exhibits filed with, or incorporated by reference into, this Registration Statement:

     

      Exhibit
    Number
      Description
      4.1   Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement on Form S-1, File No. 333-184930, filed with the SEC on November 14, 2012).
           
      4.2   Amended and Restated By-Laws of the Registrant (incorporated by reference to Exhibit 3.2 to the Company’s Registration Statement on Form S-1, File No. 333-184930, as amended on November 26, 2012).
           
      4.3   Supernus Pharmaceuticals, Inc. Amended and Restated 2021 Equity Incentive Plan (previously filed as Appendix A to the Registrant’s Proxy Statement dated April 29, 2024 relating to the Registrant’s 2024 Annual Meeting of Stockholders, incorporated herein by reference).
           
      5.1   Opinion of Saul Ewing LLP.
           
      23.1   Consent of KPMG LLP.
           
      23.2   Consent of Saul Ewing LLP (included in the opinion filed as Exhibit 5.1 to this Registration Statement).
           
      24.1   Power of Attorney (included on signature page of this Registration Statement).
           
      107   Filing Fee Table (filed herewith)

     

    3 

     

     

    Item 9.Undertakings

     

    (a) The undersigned Registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement;

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

     

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the registration statement is on Form S-8 and the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the SEC by the Registrant pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement.

     

    (2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.

     

    4 

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Rockville, State of Maryland, on June 17, 2024.

     

      SUPERNUS PHARMACEUTICALS, INC.
       
      By: /s/ Jack A. Khattar

      Name: Jack A. Khattar
      Title: President and Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby makes, constitutes and appoints Jack A. Khattar and Timothy C. Dec, and each of them, with full power to act without the other, such person’s true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in such person’s name, place and stead, in any and all capacities to sign any and all amendments to this Registration Statement, including post-effective amendments, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in connection therewith, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or any substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities and on the date indicated.

     

    Signature Title   Date
             
    /s/ Jack A. Khattar   President and Chief Executive Officer and Director   June 17, 2024
    Jack A. Khattar   (Principal Executive Officer)    
             
    /s/ Timothy C. Dec   Senior Vice President, Chief Financial Officer   June 17, 2024
    Timothy C. Dec   (Principal Financial Officer and Principal Accounting Officer)    
             
    /s/ Charles W. Newhall, III   Director and Chairman of the Board   June 17, 2024
    Charles W. Newhall, III        
             
    /s/ Carrolee Barlow, M.D., Ph.D.   Director   June 17, 2024
    Carrolee Barlow, M.D., Ph.D.        
             
    /s/ Georges Gemayel, Ph.D.   Director   June 17, 2024
    Georges Gemayel, Ph.D.        
             
    /s/ Frederick M. Hudson   Director   June 17, 2024
    Frederick M. Hudson        
             
    /s/ Bethany L. Sensenig   Director   June 17, 2024
    Bethany L. Sensenig        

     

    5 

      

    Get the next $SUPN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SUPN

    DatePrice TargetRatingAnalyst
    10/9/2025$65.00Neutral → Overweight
    Piper Sandler
    7/30/2025$42.00Neutral → Overweight
    Cantor Fitzgerald
    2/19/2025$57.00 → $36.00Overweight → Neutral
    Cantor Fitzgerald
    1/6/2025$57.00Overweight
    Cantor Fitzgerald
    9/11/2024$41.00 → $36.00Overweight → Neutral
    Piper Sandler
    1/3/2023$44.00 → $45.00Buy
    Jefferies
    12/1/2021$40.00 → $44.00Buy
    Jefferies
    More analyst ratings

    $SUPN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hudson Frederick M. exercised 15,000 shares at a strike of $12.98, increasing direct ownership by 32% to 61,307 units (SEC Form 4)

    4 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Issuer)

    1/12/26 4:09:47 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Chief Tech. Ops. Officer Mottola Frank exercised 20,000 shares at a strike of $28.82 and sold $1,008,150 worth of shares (20,000 units at $50.41) (SEC Form 4)

    4 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Issuer)

    12/22/25 4:04:25 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sr. VP of IP, CSO Bhatt Padmanabh P. converted options into 1,500 shares and sold $31,552 worth of shares (710 units at $44.44), increasing direct ownership by 6% to 14,508 units (SEC Form 4)

    4 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Issuer)

    12/19/25 4:05:32 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SUPN
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Supernus Pharmaceuticals Inc.

    SCHEDULE 13G - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)

    2/2/26 4:33:37 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Filer)

    1/28/26 5:28:48 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Supernus Pharmaceuticals Inc.

    SCHEDULE 13G/A - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)

    1/21/26 1:21:12 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SUPN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Supernus Pharma upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Supernus Pharma from Neutral to Overweight and set a new price target of $65.00

    10/9/25 8:22:44 AM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Pharma upgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald upgraded Supernus Pharma from Neutral to Overweight and set a new price target of $42.00

    7/30/25 7:19:36 AM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Pharma downgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald downgraded Supernus Pharma from Overweight to Neutral and set a new price target of $36.00 from $57.00 previously

    2/19/25 7:05:55 AM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SUPN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lunai Bioworks, Inc. Issues Letter to Shareholders

    SACRAMENTO, Calif. , Feb. 9, 2026 /PRNewswire/ -- Dear Shareholders, We have completed our AI platform in the last 12 months and now it is commercial. Negotiations are moving forward with several pharmaceutical and drug discovery companies. Partnerships and collaborations are imminent. Why? -because Lunai Bioworks operates a closed loop AI system that is truly disruptive (and complementary) to current discovery platforms and that turns complex biology into real-world action in several ways with less cash burn and new revenue streams. Our Augusta platform starts with real biolo

    2/9/26 11:14:00 AM ET
    $LNAI
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference

    ROCKVILLE, Md., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will present at the Bank of America Securities 2025 CNS Therapeutics Virtual Conference on Monday, December 8, 2025, at 3:20 p.m. ET. Investors interested in arranging a meeting with company management during the conference should contact the Bank of America conference coordinator. A live audio webcast of the presentation can be accessed here or by visiting Events & Presenta

    12/3/25 4:05:00 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference

    ROCKVILLE, Md., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025, at 4:00 p.m. ET at the Lotte New York Palace in New York City. Investors interested in arranging a meeting with company management during the conference should contact the Piper Sandler conference coordinator. A live audio webcast of the presentation can b

    11/21/25 4:06:00 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SUPN
    Leadership Updates

    Live Leadership Updates

    View All

    Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey

    Jay is sharing his story of receiving an ADHD diagnosis and eventually finding his treatment approach with Qelbree15.7 million U.S. children, teens and adults estimated to have been diagnosed with ADHD1,2 ROCKVILLE, Md., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Television personality and sports reporter Jay Glazer is opening up about his personal experiences with attention-deficit/hyperactivity disorder (ADHD) – one of the most common psychiatric diagnoses affecting approximately 10 million adults in the U.S. – and with Qelbree (viloxazine extended-release capsules), a nonstimulant medication for the treatment of ADHD.3 Glazer, who has always been outspoken about his mental health struggles, wa

    10/16/23 5:34:21 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SUPN
    Financials

    Live finance-specific insights

    View All

    Supernus Announces Third Quarter 2025 Financial Results

    Combined revenues of the Company's four growth products increased 52% to $149.2 million in the third quarter of 2025, compared to the same period in 2024. This strong growth was driven by an increase in net sales of Qelbree® and GOCOVRI®, and the addition of sales from ZURZUVAE® and ONAPGO™.Total revenues were $192.1 million in the third quarter of 2025, a 9% increase compared to the same period in 2024.Completed the acquisition of Sage Therapeutics, Inc. (Sage) on July 31, 2025.Cash, cash equivalents and current marketable securities were approximately $281.2 million at September 30, 2025.Increasing full year 2025 revenue guidance and updating full year 2025 operating earnings (loss) guidan

    11/4/25 4:01:00 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

    ROCKVILLE, Md., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report third quarter 2025 financial and business results after the market closes on Tuesday, November 4, 2025. Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to present the third quarter 2025 financial and business results on Tuesday, November 4, 2025, at 4:30 p.m. ET. Following management's prepared remarks and discussion of business results, the call will

    10/21/25 5:00:19 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Announces Second Quarter 2025 Financial Results

    Net sales of Qelbree® increased 31% in the second quarter of 2025, compared to the same period in 2024. Net sales of Qelbree of $77.6 million and $142.3 million in the second quarter and first six months of 2025, respectively. Net sales of GOCOVRI® increased 16% in the second quarter of 2025, compared to the same period in 2024. Net sales of GOCOVRI of $36.7 million and $67.4 million in the second quarter and first six months of 2025, respectively. ONAPGO™ (apomorphine hydrochloride) launched in April 2025.Total revenues were $165.5 million and $315.3 million for the three and six months ended June 30, 2025, respectively, compared to $168.3 million and $312.0 million, respectively, for the s

    8/5/25 4:05:40 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SUPN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Supernus Pharmaceuticals Inc.

    SC 13G/A - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)

    11/14/24 5:14:42 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Supernus Pharmaceuticals Inc.

    SC 13G/A - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)

    11/1/24 4:35:56 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Supernus Pharmaceuticals Inc.

    SC 13G - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)

    10/31/24 11:55:00 AM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care